Mats Jerkeman

Mats Jerkeman

Lund University - Lund / Sweden
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 1391138
Lunds Universitet
person_outline Mats Jerkeman's MOST POPULAR ARTICLES
1-) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 …CH Geisler, A Kolstad, A Laurell, NS Andersen, LB Pedersen, ...Blood, The Journal of the American Society of Hematology 112 (7), 2687-2693, 20086932008
2-) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyM Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, ...The Lancet 387 (10020), 770-778, 20164362016
3-) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ...Annals of Oncology 32 (3), 298-308, 20213562021
4-) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapyCW Eskelund, C Dahl, JW Hansen, M Westman, A Kolstad, LB Pedersen, ...Blood, The Journal of the American Society of Hematology 130 (17), 1903-1910, 20173992017
5-) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma RegistryF Ellin, J Landström, M Jerkeman, T RelanderBlood, The Journal of the American Society of Hematology 124 (10), 1570-1577, 20143952014